` STIM (Neuronetics Inc) vs S&P 500 Comparison - Alpha Spread

STIM
vs
S&P 500

Over the past 12 months, STIM has outperformed S&P 500, delivering a return of 21% compared to the S&P 500's 8% growth.

Stocks Performance
STIM vs S&P 500

Loading
STIM
S&P 500
Add Stock

Performance Gap
STIM vs S&P 500

Loading
STIM
S&P 500
Difference

Performance By Year
STIM vs S&P 500

Loading
STIM
S&P 500
Add Stock

Competitors Performance
Neuronetics Inc vs Peers

Neuronetics Inc
Glance View

Market Cap
279m USD
Industry
Health Care

Neuronetics, Inc. commercial stage medical technology company, which engages in the designing, developing and marketing products for the patients suffering from psychiatric disorders. The company is headquartered in Malvern, Pennsylvania and currently employs 175 full-time employees. The company went IPO on 2018-06-28. The firm is focused on designing, developing, and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The firm intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The firm sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.

STIM Intrinsic Value
5.82 USD
Undervaluation 27%
Intrinsic Value
Price
Back to Top